• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Eli Lilly neuroscience chief steps down

Eli Lilly neuroscience chief steps down

March 1, 2011
CenterWatch Staff

Faced with several clinical setbacks, Eli Lilly neuroscience chief David Bredt has left the company. Bredt joined Lilly in 2004, according to the Wall Street Journal.

The most notable of Lilly’s neurological drug setbacks was the Alzheimer's drug semagacestat, according to Fierce Biotech. The company halted further development of the drug in August 2010 after clinical trials revealed that semagacestat not only failed its endpoints on slowing progression, but also worsened the condition of the patients on the drug. More recently, an FDA panel rejected Lilly's Amyvid (florbetapir), an imaging chemical for Alzheimer's, saying Lilly needs to set up a training program to show physicians how to use the compound.

A spokesperson for Lilly told the WSJ that Bredt left voluntarily and that the company remains committed to neuroscience research. Almost a fifth of Lilly's pipeline drugs address neurological conditions, including late-stage compounds solanezumab for Alzheimer’s and Neri for depression.

 

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing